Yale Hereditary Kidney Cancer and Genetic Assessment Program
The Yale Kidney Cancer and Genetic Assessment Program launched a specialized program in 2013 to evaluate and manage individuals who may have kidney cancer perhaps caused by heredity or acquired genetic alterations. This program was specifically designed to assist the unmet needs of those patients with less common forms or unusual presentations of kidney cancer as well as to assist their community physicians who may be less familiar with genetic testing and the specifics of clinical management. This comprehensive program is designed to evaluate and treat the following types of patients:
- Patients with early onset kidney tumors (presenting at age 45 or less)
- Patients with bilateral or multifocal kidney tumors
- Patients with significant family history [one (1) relative or two (2) relatives] with kidney tumors
- Personal or family history of other cancers including tumors of the pancreas, uterus, thyroid, breast, brain/spine, adrenal gland, and melanoma
- Associated dermatologic skin conditions with or without a family history of kidney cancer such as fibrofolliculomas, leiomyomas, angiofibromas, etc.
The program contains a team of experts within the Yale New Haven Hospital and Smilow Cancer Center focused on managing cancer patients, including clinicians with a specific interest in treating hereditary cancer syndromes. As part of this program, we have experienced genetic counselors, a clinical geneticist familiar with next generation testing, a molecular diagnostic team, and a partnership with the newly-established Yale Cancer Genetics and Prevention Program.
Besides performing genetic testing for known kidney cancer genes using in-house CLIA certified genetic labs, our team also is interested in novel gene discovery. By using next generating sequencing techniques, we expect to find new causes that contribute to familial cancer predisposition, some which will result in therapeutic implications.
The Smilow Cancer Center is one of 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. Additionally, our team’s expertise in the management of complex forms of kidney cancer has recently led to a special designation by the VHL Family Alliance as one of eight Comprehensive Clinical Care Centers for hereditary kidney cancer. This designation highlights our commitment and ability to manage highly complex kidney cancer conditions.
The Program Director also serves as one of three members on the kidney cancer team for the NCI Physician’s Desk Query Cancer Genetics Editorial Board. This group continually updates NCI's website to provide the public with the latest management strategies for hereditary kidney cancer. Additionally, our molecular diagnostics team developed Clinical Laboratory Improvement Methods (CLIA)-certified methods for tumor characterization (PCR and FISH), specifically designed to identify acquired genetic events found in tumors in young adults. This ensures we will remain at the forefront in understanding and treating genetic causes of kidney cancer disease.
If you are interested in being evaluated by Yale’s Hereditary Kidney Cancer and Genetic Assessment Program or want to schedule an in-person or remote consultation, please call one of the following numbers:
- For patients with a recent kidney cancer diagnosis (<1 yr.) or needing further kidney cancer treatment: (203) 785-2815
- For patients with concerning features for a hereditary kidney cancer syndrome or prior kidney cancer treatment (>1 yr.): (203) 200-4362